Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies

References

• Isager P, Engholm G, Overgaard J, Storm H. Uveal and conjunctival malignant melanoma in Denmark 1943–97: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol. 2006;13(2):85–96. doi:10.1080/09286580600553330
   PubMed Web of Science ®Google Scholar
• Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and non-cutaneous melanoma: a summary of 84,836 cases from the past decade. The American college of surgeons commission on cancer and the American cancer society. Cancer. 1998;83(8):1664–1678. doi:10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Triay E, Bergman L, Nilsson B, All-Ericsson C, Seregard S. Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol. 2009;93(11):1524–1528. doi:10.1136/bjo.2009.157933
   PubMed Web of Science ®Google Scholar
• Yu GP, Hu DN, McCormick S, Finger PT. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol. 2003;135(6):800–806. doi:10.1016/S0002-9394(02)02288-2
   PubMed Web of Science ®Google Scholar
• Kaštelan S, Gverović Antunica A, Beketić Orešković L, Salopek Rabatić J, Kasun B, Bakija I. Conjunctival melanoma - epidemiological trends and features. Pathol Oncol Res. 2018;24(4):787–796.
   Web of Science ®Google Scholar
• Virgili G, Parravano M, Gatta G, et al. Incidence and survival of patients with conjunctival melanoma in Europe. JAMA Ophthalmol. 2020;138(6):601–608. doi:10.1001/jamaophthalmol.2020.0531
   PubMed Web of Science ®Google Scholar
• Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118(2):389–95.e952. doi:10.1016/j.ophtha.2010.06.021
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, Mashayekhi A, et al. Primary acquired melanosis of the conjunctiva: experience with 311 eyes. Trans Am Ophthalmol Soc. 2007;105:61–72.
   PubMedGoogle Scholar
• Shields CL, Shields JA, Gündüz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118(11):1497–1507. doi:10.1001/archopht.118.11.1497
   PubMedGoogle Scholar
• Damato B, Coupland SE. Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. Clin Exp Ophthalmol. 2008;36(8):786–795. doi:10.1111/j.1442-9071.2008.01888.x
   PubMed Web of Science ®Google Scholar
• Kenawy N, Kalirai H, Sacco JJ, et al. Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome. Pigment Cell Melanoma Res. 2019;32(4):564–575. doi:10.1111/pcmr.12767
   Web of Science ®Google Scholar
• Shields CL, Kaliki S, Al-Dahmash SA, Lally SE, Shields JA. American joint committee on cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes. Ophthalmic Plast Reconstr Surg. 2012;28(5):313–323. doi:10.1097/IOP.0b013e3182611670
   PubMed Web of Science ®Google Scholar
• Shields CL, Fasiuddin AF, Mashayekhi A, Shields JA. Conjunctival nevi: clinical features and natural course in 410 consecutive patients. Arch Ophthalmol. 2004;122(2):167–175. doi:10.1001/archopht.122.2.167
   PubMedGoogle Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–1284. doi:10.1016/j.bbamcr.2006.10.001
   PubMed Web of Science ®Google Scholar
• Cao J, Heijkants RC, Jochemsen AG, et al. Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy. Oncotarget. 2016;8(35):58021–58036. doi:10.18632/oncotarget.10770
   Google Scholar
• Scholz SL, Cosgarea I, Süßkind D, et al. NF1 mutations in conjunctival melanoma. Br J Cancer. 2018;118(9):1243–1247. doi:10.1038/s41416-018-0046-5
   PubMed Web of Science ®Google Scholar
• Wallander ML, Layfield LJ, Emerson LL, et al. KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol. 2011;24(8):1031–1035. doi:10.1038/modpathol.2011.57
   Web of Science ®Google Scholar
• Akbani R, Akdemir K, Aksoy B, Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–1696. doi:10.1016/j.cell.2015.05.044
   PubMed Web of Science ®Google Scholar
• Brash DE. UV signature mutations. Photochem Photobiol. 2015;91(1):15–26. doi:10.1111/php.12377
   PubMed Web of Science ®Google Scholar
• Swaminathan SS, Field MG, Sant D, et al. Molecular characteristics of conjunctival melanoma using whole-exome sequencing. JAMA Ophthalmol. 2017;135(12):1434–1437. doi:10.1001/jamaophthalmol.2017.4837
   PubMed Web of Science ®Google Scholar
• Rivolta C, Royer-Bertrand B, Rimoldi D, et al. UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation. J Hum Genet. 2016;61(4):361–362. doi:10.1038/jhg.2015.152
   PubMed Web of Science ®Google Scholar
• Gear H, Williams H, Kemp EG, Roberts F. BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci. 2004;45(8):2484–2488. doi:10.1167/iovs.04-0093
   PubMed Web of Science ®Google Scholar
• Goldenberg-Cohen N, Cohen Y, Rosenbaum E, et al. T1799A BRAF mutations in conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci. 2005;46(9):3027–3030. doi:10.1167/iovs.04-1449
   Web of Science ®Google Scholar
• Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(21):6821–6828. doi:10.1158/1078-0432.CCR-08-0575
   PubMed Web of Science ®Google Scholar
• Lake SL, Jmor F, Dopierala J, Taktak AF, Coupland SE, Damato BE. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci. 2011;52(8):5598–5604. doi:10.1167/iovs.10-6934
   PubMed Web of Science ®Google Scholar
• Griewank KG, Westekemper H, Murali R, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res. 2013;19(12):3143–3152. doi:10.1158/1078-0432.CCR-13-0163
   PubMed Web of Science ®Google Scholar
• Griewank KG, Murali R, Schilling B, et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumors. Br J Cancer. 2013;109(2):497–501. doi:10.1038/bjc.2013.312
   PubMed Web of Science ®Google Scholar
• Weber JL, Smalley KS, Sondak VK, Gibney GT. Conjunctival melanomas harbor BRAF and NRAS mutations–letter. Clin Cancer Res. 2013;19(22):6329–6330. doi:10.1158/1078-0432.CCR-13-2007
   Web of Science ®Google Scholar
• Koopmans AE, Ober K, Dubbink HJ, et al. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci. 2014;55(9):6024–6030. doi:10.1167/iovs.14-14901
   PubMed Web of Science ®Google Scholar
• Larsen AC, Dahmcke CM, Dahl C, et al. A retrospective review of conjunctival melanoma presentation, treatment, and outcome and an investigation of features associated with BRAF mutations. JAMA Ophthalmol. 2015;133(11):1295–1303. doi:10.1001/jamaophthalmol.2015.3200
   PubMed Web of Science ®Google Scholar
• Dagi Glass LR, Lawrence DP, Jakobiec FA, Freitag SK. Conjunctival melanoma responsive to combined systemic BRAF/MEK inhibitors. Ophthalmic Plast Reconstr Surg. 2017;33(5):e114–e116. doi:10.1097/IOP.0000000000000833
   PubMed Web of Science ®Google Scholar
• Maleka A, Åström G, Byström P, Ullenhag GJ. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. BMC Cancer. 2016;16(1):634. doi:10.1186/s12885-016-2657-7
   Web of Science ®Google Scholar
• Larsen AC, Dahl C, Dahmcke CM, et al. BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions. Acta Ophthalmol. 2016;94(5):463–470. doi:10.1111/aos.13007
   Web of Science ®Google Scholar
• Pinto Torres S, André T, Gouveia E, Costa L, Passos MJ. Systemic treatment of metastatic conjunctival melanoma. Case Rep Oncol Med. 2017;2017:4623964.
   Google Scholar
• Demirci H, Demirci FY, Ciftci S, et al. Integrative exome and transcriptome analysis of conjunctival melanoma and its potential application for personalized therapy. JAMA Ophthalmol. 2019;137(12):1444–1448. doi:10.1001/jamaophthalmol.2019.4237
   Web of Science ®Google Scholar
• El Zaoui I, Bucher M, Rimoldi D, et al. Conjunctival melanoma targeted therapy: MAPK and PI3K/mTOR pathways inhibition. Invest Ophthalmol Vis Sci. 2019;60(7):2764–2772. doi:10.1167/iovs.18-26508
   Web of Science ®Google Scholar
• Finger PT, Pavlick AC. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series. J Immunother Cancer. 2019;7(1):83. doi:10.1186/s40425-019-0555-7
   PubMed Web of Science ®Google Scholar
• Kiyohara T, Tanimura H, Miyamoto M, et al. Two cases of BRAF-mutated, bulbar conjunctival melanoma, and review of the published literature. Clin Exp Dermatol. 2020;45(2):207–211. doi:10.1111/ced.14060
   PubMed Web of Science ®Google Scholar
• Chang M, Lally SE, Dalvin LA, Orloff MM, Shields CL. Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy. Indian J Ophthalmol. 2019;67(12):2071–2073. doi:10.4103/ijo.IJO_663_19
   PubMed Web of Science ®Google Scholar
• Rossi E, Maiorano BA, Pagliara MM, et al. Dabrafenib and trametinib in BRAF mutant metastatic conjunctival melanoma. Front Oncol. 2019;9:232. doi:10.3389/fonc.2019.00232
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954. doi:10.1038/nature00766
   PubMed Web of Science ®Google Scholar
• Glitza IC, Davies MA. Genotyping of cutaneous melanoma. Chin Clin Oncol. 2014;3(3):27.
   Google Scholar
• Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008;1(4):395–405. doi:10.1016/j.molonc.2007.12.003
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19–20. doi:10.1038/ng1054
   PubMed Web of Science ®Google Scholar
• Uribe P, Wistuba II, González S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol. 2003;25(5):365–370. doi:10.1097/00000372-200310000-00001
   PubMed Web of Science ®Google Scholar
• Cohen Y, Goldenberg-Cohen N, Parrella P, et al. Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(7):2876–2878. doi:10.1167/iovs.02-1329
   Web of Science ®Google Scholar
• Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24.
   PubMed Web of Science ®Google Scholar
• Spendlove HE, Damato BE, Humphreys J, Barker KT, Hiscott PS, Houlston RS. BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res. 2004;14(6):449–452. doi:10.1097/00008390-200412000-00003
   PubMed Web of Science ®Google Scholar
• Bol KF, Donia M, Heegaard S, Kiilgaard JF, Svane IM. Genetic biomarkers in melanoma of the ocular region: what the medical oncologist should know. Int J Mol Sci. 2020;21(15):5231. doi:10.3390/ijms21155231
   Web of Science ®Google Scholar
• Larsen AC. Conjunctival malignant melanoma in Denmark. Epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile. Acta Ophthalmol. 2016;94(8):842. doi:10.1111/aos.13207
   Web of Science ®Google Scholar
• Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS. 2007;115(10):1161–1176. doi:10.1111/j.1600-0463.2007.apm_855.xml.x
   PubMed Web of Science ®Google Scholar
• Cruz F 3rd, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 2003;63(18):5761–5766.
   Web of Science ®Google Scholar
• Muñoz-Couselo E, Adelantado EZ, Ortiz C, García JS, Perez-Garcia J. NRAS-mutant melanoma: current challenges and future prospect. Onco Targets Ther. 2017;10:3941–3947. doi:10.2147/OTT.S117121
   PubMed Web of Science ®Google Scholar
• Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014–4023. doi:10.1002/cncr.26724
   PubMed Web of Science ®Google Scholar
• Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet. 2015;47(9):996–1002. doi:10.1038/ng.3361
   PubMed Web of Science ®Google Scholar
• Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104(4):593–604. doi:10.1016/S0092-8674(01)00245-8
   Web of Science ®Google Scholar
• Hintzsche JD, Gorden NT, Amato CM, et al. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res. 2017;27(3):189–199. doi:10.1097/CMR.0000000000000345
   PubMed Web of Science ®Google Scholar
• Sheng X, Li S, Chi Z, et al. Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients. Br J Ophthalmol. 2015;99(7):990–996. doi:10.1136/bjophthalmol-2014-305730
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340–4346.
   PubMed Web of Science ®Google Scholar
• Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 2001;25(7):571–576. doi:10.1016/S0145-2126(01)00028-5
   PubMed Web of Science ®Google Scholar
• Gong HZ, Zheng HY, Li J. The clinical significance of KIT mutations in melanoma: a meta-analysis. Melanoma Res. 2018;28(4):259–270.
   Web of Science ®Google Scholar
• Pópulo H, Soares P, Rocha AS, Silva P, Lopes JM. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res. 2010;20(2):107–117. doi:10.1097/CMR.0b013e32832ccd09
   PubMed Web of Science ®Google Scholar
• Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where next for melanoma therapy? Br J Cancer. 2015;112(2):217–226.
   PubMed Web of Science ®Google Scholar
• Tsao H, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol. 2003;49(5):865–872. doi:10.1016/S0190-9622(03)02473-3
   PubMed Web of Science ®Google Scholar
• Westekemper H, Karimi S, Süsskind D, et al. Expression of HSP 90, PTEN and Bcl-2 in conjunctival melanoma. Br J Ophthalmol. 2011;95(6):853–858. doi:10.1136/bjo.2010.183939
   Web of Science ®Google Scholar
• Hugdahl E, Kalvenes MB, Mannelqvist M, Ladstein RG, Akslen LA. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma. Br J Cancer. 2018;118(1):98–105.
   PubMed Web of Science ®Google Scholar
• Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–56. doi:10.1038/35065016
   PubMed Web of Science ®Google Scholar
• Mishan MA, Ahmadiankia N, Bahrami AR. CXCR4 and CCR7: two eligible targets in targeted cancer therapy. Cell Biol Int. 2016;40(9):955–967. doi:10.1002/cbin.10631
   Web of Science ®Google Scholar
• Dobner BC, Riechardt AI, Joussen AM, Englert S, Bechrakis NE. Expression of hematogenous and lymphogenous chemokine receptors and their ligands on uveal malignant melanoma in association with liver metastasis. Acta Ophthalmol. 2012;90(8):e638–e644. doi:10.1111/j.1755-3768.2012.02515.x
   Web of Science ®Google Scholar
• Mitchell B, Mahalingam M. The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on malignant melanoma. Histol Histopathol. 2014;29:1539–1546.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
   PubMed Web of Science ®Google Scholar
• van Ipenburg JA, de Waard NE, Naus NC, Jager MJ, Paridaens D, Verdijk RM. Chemokine receptor expression pattern correlates to progression of conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci. 2019;60(8):2950–2957. doi:10.1167/iovs.19-27162
   PubMed Web of Science ®Google Scholar
• Rossi E, Schinzari G, Maiorano BA, et al. Conjunctival melanoma: genetic and epigenetic insights of a distinct type of melanoma. Int J Mol Sci. 2019;20(21):5447. doi:10.3390/ijms20215447
   PubMed Web of Science ®Google Scholar
• McNamara M, Felix C, Davison EV, Fenton M, Kennedy SM. Assessment of chromosome 3 copy number in ocular melanoma using fluorescence in situ hybridization. Cancer Genet Cytogenet. 1997;98(1):4–8.
   PubMedGoogle Scholar
• Vajdic CM, Hutchins AM, Kricker A, et al. Chromosomal gains and losses in ocular melanoma detected by comparative genomic hybridization in an Australian population-based study. Cancer Genet Cytogenet. 2003;144(1):12–17. doi:10.1016/S0165-4608(02)00868-3
   Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–269. doi:10.1038/nrc1840
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kunz M. MicroRNAs in melanoma biology. Adv Exp Med Biol. 2013;774:103–120.
   Web of Science ®Google Scholar
• Xu Y, Brenn T, Brown ER, Doherty V, Melton DW. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumor suppressors. Br J Cancer. 2012;106(3):553–561. doi:10.1038/bjc.2011.568
   PubMed Web of Science ®Google Scholar
• Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010;70(10):4163–4173. doi:10.1158/0008-5472.CAN-09-4512
   PubMed Web of Science ®Google Scholar
• Larsen AC, Mikkelsen LH, Borup R, et al. MicroRNA expression profile in conjunctival melanoma. Invest Ophthalmol Vis Sci. 2016;57(10):4205–4212. doi:10.1167/iovs.16-19862
   Web of Science ®Google Scholar
• Waizenegger IC, Baum A, Steurer S, et al. A novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation. Mol Cancer Ther. 2016;15(3):354–365. doi:10.1158/1535-7163.MCT-15-0617
   PubMed Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–599. doi:10.1038/nature09454
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Arozarena I. The complexity of the ERK/MAP-kinase pathway and the treatment of melanoma skin cancer. Front Cell Dev Biol. 2016;4:33.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714. doi:10.1056/NEJMoa1112302
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516. doi:10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar
• Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4(1):94–109.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114. doi:10.1056/NEJMoa1203421
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888. doi:10.1056/NEJMoa1406037
   PubMed Web of Science ®Google Scholar
• Posch C, Moslehi H, Feeney L, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci USA. 2013;110(10):4015–4020. doi:10.1073/pnas.1216013110
   PubMed Web of Science ®Google Scholar
• Chamcheu JC, Roy T, Uddin MB, et al. Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy. Cells. 2019;8(8):803. doi:10.3390/cells8080803
   PubMed Web of Science ®Google Scholar
• Riechardt AI, Maier AK, Nonnenmacher A, et al. B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720. Br J Ophthalmol. 2015;99(12):1739–1745. doi:10.1136/bjophthalmol-2015-306689
   Web of Science ®Google Scholar
• Griewank KG, Westekemper H, Schilling B, et al. Conjunctival melanomas harbor BRAF and NRAS mutations–response. Clin Cancer Res. 2013;19(22):6331–6332. doi:10.1158/1078-0432.CCR-13-2368
   Web of Science ®Google Scholar
• Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicenter, safety study. Lancet Oncol. 2014;15(4):436–444. doi:10.1016/S1470-2045(14)70051-8
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122–136. doi:10.1177/1758834014566428
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, Phase 3 randomized controlled trial. Lancet. 2012;380(9839):358–365. doi:10.1016/S0140-6736(12)60868-X
   PubMed Web of Science ®Google Scholar
• Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a Phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):773–781. doi:10.1016/S1470-2045(12)70270-X
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–214. doi:10.1016/j.cell.2015.03.030
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546. doi:10.1056/NEJMoa1910836
   PubMed Web of Science ®Google Scholar
• Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and novel combinations in the treatment of melanoma-an update. J Clin Med. 2020;9(1):223.
   PubMed Web of Science ®Google Scholar
• Wierenga APA, Cao J, Luyten GPM, Jager MJ. Immune checkpoint inhibitors in uveal and conjunctival melanoma. Int Ophthalmol Clin. 2019;59(2):53–63. doi:10.1097/IIO.0000000000000263
   Google Scholar
• Jindal V. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma. Chin Clin Oncol. 2018;7(1):8. doi:10.21037/cco.2018.01.05
   PubMed Web of Science ®Google Scholar
• Ford J, Thuro BA, Thakar S, Hwu WJ, Richani K, Esmaeli B. Immune checkpoint inhibitors for treatment of metastatic melanoma of the orbit and ocular adnexa. Ophthalmic Plast Reconstr Surg. 2017;33(4):e82–e85. doi:10.1097/IOP.0000000000000790
   PubMed Web of Science ®Google Scholar
• Sagiv O, Thakar SD, Kandl TJ, et al. Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma. JAMA Ophthalmol. 2018;136(11):1236–1241. doi:10.1001/jamaophthalmol.2018.3488
   PubMed Web of Science ®Google Scholar
• Kini A, Fu R, Compton C, Miller DM, Ramasubramanian A. Pembrolizumab for recurrent conjunctival melanoma. JAMA Ophthalmol. 2017;135(8):891–892.
   Web of Science ®Google Scholar
• Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.
   PubMed Web of Science ®Google Scholar
• Coureau M, Meert AP, Berghmans T, Grigoriu B. Efficacy and toxicity of immune -checkpoint inhibitors in patients with preexisting autoimmune disorders. Front Med (Lausanne). 2020;7:137. doi:10.3389/fmed.2020.00137
   Web of Science ®Google Scholar
• Bajwa R, Cheema A, Khan T, et al. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res. 2019;11(4):225–236. doi:10.14740/jocmr3750
   PubMedGoogle Scholar
• Aivazian K, Long GV, Sinclair EC, Kench JG, McKenzie CA. Histopathology of pembrolizumab-induced hepatitis: a case report. Pathology. 2017;49(7):789–792. doi:10.1016/j.pathol.2017.07.010
   PubMed Web of Science ®Google Scholar
• Friedman CF, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst. 2016;109(4):djw260. doi:10.1093/jnci/djw260
   Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. doi:10.1056/NEJMoa1609214
   PubMed Web of Science ®Google Scholar
• Seki T, Yasuda A, Oki M, et al. Secondary adrenal insufficiency following nivolumab therapy in a patient with metastatic renal cell carcinoma. Tokai J Exp Clin Med. 2017;42(3):115–120.
   PubMedGoogle Scholar
• Kastrisiou M, Kostadima FL, Kefas A, et al. Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. ESMO Open. 2017;2(4):e000217. doi:10.1136/esmoopen-2017-000217
   PubMed Web of Science ®Google Scholar
• Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol. 2008;181(4):2513–2521. doi:10.4049/jimmunol.181.4.2513
   PubMed Web of Science ®Google Scholar
• Wang W, Lam WC, Chen L. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2019;68(1):85–95. doi:10.1007/s00262-018-2260-7
   Web of Science ®Google Scholar
• Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM. Ipilimumab-induced ocular and orbital inflammation–a case series and review of the literature. Ocul Immunol Inflamm. 2016;24(2):140–146.
   PubMed Web of Science ®Google Scholar
• Tuomaala S, Kivelä T. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy. Ophthalmology. 2004;111(4):816–821. doi:10.1016/j.ophtha.2003.11.001
   Web of Science ®Google Scholar